N. Yu. Velts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
N. Yu. Velts has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Н. Ю. Вельц
Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации
24 shared publications- E. O. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products
14 shared publications - G. V. Kutekhova
Scientific Centre for Expert Evaluation of Medicinal Products
13 shared publications - M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
10 shared publications - E. V. Shubnikova
Scientific Centre for Expert Evaluation of Medicinal Products
9 shared publications - Renad Nikolaevich Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products
8 shared publications
Latest Publications
- Open Access
- 24 June 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (2) , 127-137
Pharmacovigilance in the Geriatric Population: Analysis of Risk Management Plans for Medicinal Products in Russia in 2024
INTRODUCTION. Geriatric patients are the fastest growing demographic group, accounting for over half of all medicinal product users. Pharmacovigilance in this population is influenced by age-related physiological changes and social factors. Risk management plans (RMPs), developed by marketing authorisation holders, play a preventive role in managing the risks associated with the use of medicinal products in elderly patients.AIM. This study aimed to evaluate the completeness of information on the geriatric group within target populations in RMPs for medicinal products launched in the Russian pharmaceutical market in 2024.MATERIALS AND METHODS. This study analysed 110 RMPs for medicinal products potentially applicable to geriatric populations, submitted to the Scientific Centre for Expert Evaluation of Medicinal Products between January and December 2024. All the documents included full modules and sections.RESULTS. The analysis revealed critical gaps in RMPs data for geriatric populations, including the epidemiology of indication(s) and target population(s) (these data were missing in 52.0% of cases); clinical trial exposure (patients over 60 years were excluded from clinical trials in 47.3% of cases); populations not studied in clinical trials (these data were unreported in 63.6% of cases); post-authorisation experience in elderly or senile patients (these data were missing in 83.6% of cases); and potential harm from overdose (risk warnings were absent in 96.4% of cases). There were no additional risk minimisation measures for emphasising the considerations for medicinal product use in the geriatric population in the analysed documents.CONCLUSIONS. When drafting RMPs, marketing authorisation holders and medicinal product developers do not pay sufficient attention to geriatric populations and often underestimate the risks associated with medicinal product use in elderly and senile patients. The issues associated with the use of medicinal products in geriatric patients can be mitigated through rigorous risk management practices applied during pharmacotherapy. The parties concerned should consider this when drafting the summary of medicinal product characteristics and the patient information leaflet, labelling the medicinal product, and selecting the package size.
- 24 June 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (2) , 127-137
Open AccessPharmacovigilance in the Geriatric Population: Analysis of Risk Management Plans for Medicinal Products in Russia in 2024
INTRODUCTION. Geriatric patients are the fastest growing demographic group, accounting for over half of all medicinal product users. Pharmacovigilance in this population is influenced by age-related physiological changes and social factors. Risk management plans (RMPs), developed by marketing authorisation holders, play a preventive role in managing the risks associated with the use of medicinal products in elderly patients.AIM. This study aimed to evaluate the completeness of information on the geriatric group within target populations in RMPs for medicinal products launched in the Russian pharmaceutical market in 2024.MATERIALS AND METHODS. This study analysed 110 RMPs for medicinal products potentially applicable to geriatric populations, submitted to the Scientific Centre for Expert Evaluation of Medicinal Products between January and December 2024. All the documents included full modules and sections.RESULTS. The analysis revealed critical gaps in RMPs data for geriatric populations, including the epidemiology of indication(s) and target population(s) (these data were missing in 52.0% of cases); clinical trial exposure (patients over 60 years were excluded from clinical trials in 47.3% of cases); populations not studied in clinical trials (these data were unreported in 63.6% of cases); post-authorisation experience in elderly or senile patients (these data were missing in 83.6% of cases); and potential harm from overdose (risk warnings were absent in 96.4% of cases). There were no additional risk minimisation measures for emphasising the considerations for medicinal product use in the geriatric population in the analysed documents.CONCLUSIONS. When drafting RMPs, marketing authorisation holders and medicinal product developers do not pay sufficient attention to geriatric populations and often underestimate the risks associated with medicinal product use in elderly and senile patients. The issues associated with the use of medicinal products in geriatric patients can be mitigated through rigorous risk management practices applied during pharmacotherapy. The parties concerned should consider this when drafting the summary of medicinal product characteristics and the patient information leaflet, labelling the medicinal product, and selecting the package size.
- Open Access
- 29 October 2024
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 12 (4) , 420-431
Adverse Reactions to Intravenous Immunoglobulin Therapy: An Analysis of the Russian National Pharmacovigilance Database
INTRODUCTION. Human immunoglobulins have been successfully used in clinical practice to treat multiple autoimmune and inflammatory conditions, and most of the current immunoglobulins are well tolerated by patients. However, patients may develop complications associated with proteins and other components of human plasma present in immunoglobulin products. The improvement of measures to ensure the quality, efficacy, and safety of immunobiologicals, including intravenous immunoglobulins (IVIGs), requires regular monitoring of data on individual and class-related adverse drug reactions (ADRs) associated with these medicinal products. AIM. This study aimed to conduct a systematic and comprehensive assessment of information on the potential ADRs to the IVIGs of Russian marketing authorisation holders from summaries of medicinal product characteristics (SmPCs) and the Russian national pharmacovigilance database. MATERIALS AND METHODS. The study analysed the SmPCs of all the IVIGs authorised for use in Russia and the spontaneous reports of ADRs to the IVIGs of Russian marketing authorisation holders. The study was limited to the spontaneous reports submitted to the database PHARMACOVIGILANCE/MONITORING OF CLINICAL TRIALS OF MEDICINES in the Automated Information System of the Federal Service for Surveillance in Healthcare from 1 January 2020 to 30 August 2024. RESULTS. At the time of the study, there were 20 normal human IVIGs authorised in Russia, and Russian companies held marketing authorisations for 9 of these IVIGs. During the study period, there were 133 cases of ADRs associated with the IVIGs of Russian marketing authorisation holders. The most common ADRs included 41 (16.5%) cases of hyperthermia, 14 (5.6%) cases of headache, 14 (5.6%) cases of urticaria, and 14 (5.6%) cases of treatment ineffectiveness. The majority of these cases (70%) occurred when IVIGs were used for approved indications. CONCLUSIONS. All the ADRs identified in the analysis of the Russian national pharmacovigilance database were expected and consistent with the ADRs labelled in the SmPCs of the reported IVIGs. To reduce the risk of ADRs and improve the safety of IVIG therapy, it is required to develop a comprehensive approach to human IVIGs with quality assurance measures and standard use guidelines.
- 29 October 2024
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 12 (4) , 420-431
Open AccessAdverse Reactions to Intravenous Immunoglobulin Therapy: An Analysis of the Russian National Pharmacovigilance Database
INTRODUCTION. Human immunoglobulins have been successfully used in clinical practice to treat multiple autoimmune and inflammatory conditions, and most of the current immunoglobulins are well tolerated by patients. However, patients may develop complications associated with proteins and other components of human plasma present in immunoglobulin products. The improvement of measures to ensure the quality, efficacy, and safety of immunobiologicals, including intravenous immunoglobulins (IVIGs), requires regular monitoring of data on individual and class-related adverse drug reactions (ADRs) associated with these medicinal products. AIM. This study aimed to conduct a systematic and comprehensive assessment of information on the potential ADRs to the IVIGs of Russian marketing authorisation holders from summaries of medicinal product characteristics (SmPCs) and the Russian national pharmacovigilance database. MATERIALS AND METHODS. The study analysed the SmPCs of all the IVIGs authorised for use in Russia and the spontaneous reports of ADRs to the IVIGs of Russian marketing authorisation holders. The study was limited to the spontaneous reports submitted to the database PHARMACOVIGILANCE/MONITORING OF CLINICAL TRIALS OF MEDICINES in the Automated Information System of the Federal Service for Surveillance in Healthcare from 1 January 2020 to 30 August 2024. RESULTS. At the time of the study, there were 20 normal human IVIGs authorised in Russia, and Russian companies held marketing authorisations for 9 of these IVIGs. During the study period, there were 133 cases of ADRs associated with the IVIGs of Russian marketing authorisation holders. The most common ADRs included 41 (16.5%) cases of hyperthermia, 14 (5.6%) cases of headache, 14 (5.6%) cases of urticaria, and 14 (5.6%) cases of treatment ineffectiveness. The majority of these cases (70%) occurred when IVIGs were used for approved indications. CONCLUSIONS. All the ADRs identified in the analysis of the Russian national pharmacovigilance database were expected and consistent with the ADRs labelled in the SmPCs of the reported IVIGs. To reduce the risk of ADRs and improve the safety of IVIG therapy, it is required to develop a comprehensive approach to human IVIGs with quality assurance measures and standard use guidelines.
- Open Access
- 26 August 2024
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 12 (3) , 331-340
Submission of Documents on the Pharmacovigilance System as Part of the Registration Dossier within the Framework of the EAEU Procedures: Analysis of Requirements and Typical Errors
INTRODUCTION . Documents on the pharmacovigilance system of the marketing authorisation holder (MAH), including the Pharmacovigilance System Master File (PSMF) and the PSMF-based summary of the pharmacovigilance system (SPS), are a mandatory component of the registration dossier for a medicinal product. Applicants must submit and update these documents in strict accordance with the legislation of the Eurasian Economic Union (EAEU). Systematisation of the requirements for drafting and submitting documents on the pharmacovigilance system will help applicants streamline the documentation process. AIM . This study aimed to analyse the requirements for submitting either the PSMF or the SPS, depending on the EAEU marketing authorisation procedure, and to describe typical errors made by applicants when submitting these documents. DISCUSSION . The content of dossier documents on the pharmacovigilance system is regulated by the Rules of Good Pharmacovigilance Practice of the Eurasian Economic Union (Decision No. 87 of the Council of the Eurasian Economic Commission (EEC) dated 3 November 2016), and their submission is governed by the Rules of Marketing Authorisation and Assessment of Medicinal Products for Human Use (EEC Council Decision No. 78 dated 3 November 2016). MAHs are required to keep documents on the pharmacovigilance system and the corresponding registration dossiers up to date. This article summarises the specific requirements for submitting either the PSMF or the SPS, depending on the EAEU marketing authorisation procedure. Additionally, this article highlights typical errors made by MAHs when preparing documents on the pharmacovigilance system. According to the EAEU Rules of Good Pharmacovigilance Practice, the first application submitted for marketing authorisation of a medicinal product in the EAEU should include the PSMF, and subsequent applications should include the SPS as part of the registration dossier. Changes to the pharmacovigilance documents should be made in accordance with the classifier (EEC Council Decision No. 78 dated 3 November 2016). CONCLUSIONS . This analysis of the requirements for the PSMF or the SPS as part of various marketing authorisation procedures will facilitate compliance with the requirements of the EAEU legislative acts and ensure correct submission of necessary documents on the pharmacovigilance system by applicants. In addition, regulatory authorities will make fewer requests to submit missing information and grant more marketing authorisations. ERRATUM Erratum: Velts N.Yu. et al. Submission of Documents on the Pharmacovigilance System as Part of the Registration Dossier within the Framework of the EAEU Procedures: Analysis of Requirements and Typical Errors https://www.risksafety.ru/jour/article/view/476
- 26 August 2024
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 12 (3) , 331-340
Open AccessSubmission of Documents on the Pharmacovigilance System as Part of the Registration Dossier within the Framework of the EAEU Procedures: Analysis of Requirements and Typical Errors
INTRODUCTION . Documents on the pharmacovigilance system of the marketing authorisation holder (MAH), including the Pharmacovigilance System Master File (PSMF) and the PSMF-based summary of the pharmacovigilance system (SPS), are a mandatory component of the registration dossier for a medicinal product. Applicants must submit and update these documents in strict accordance with the legislation of the Eurasian Economic Union (EAEU). Systematisation of the requirements for drafting and submitting documents on the pharmacovigilance system will help applicants streamline the documentation process. AIM . This study aimed to analyse the requirements for submitting either the PSMF or the SPS, depending on the EAEU marketing authorisation procedure, and to describe typical errors made by applicants when submitting these documents. DISCUSSION . The content of dossier documents on the pharmacovigilance system is regulated by the Rules of Good Pharmacovigilance Practice of the Eurasian Economic Union (Decision No. 87 of the Council of the Eurasian Economic Commission (EEC) dated 3 November 2016), and their submission is governed by the Rules of Marketing Authorisation and Assessment of Medicinal Products for Human Use (EEC Council Decision No. 78 dated 3 November 2016). MAHs are required to keep documents on the pharmacovigilance system and the corresponding registration dossiers up to date. This article summarises the specific requirements for submitting either the PSMF or the SPS, depending on the EAEU marketing authorisation procedure. Additionally, this article highlights typical errors made by MAHs when preparing documents on the pharmacovigilance system. According to the EAEU Rules of Good Pharmacovigilance Practice, the first application submitted for marketing authorisation of a medicinal product in the EAEU should include the PSMF, and subsequent applications should include the SPS as part of the registration dossier. Changes to the pharmacovigilance documents should be made in accordance with the classifier (EEC Council Decision No. 78 dated 3 November 2016). CONCLUSIONS . This analysis of the requirements for the PSMF or the SPS as part of various marketing authorisation procedures will facilitate compliance with the requirements of the EAEU legislative acts and ensure correct submission of necessary documents on the pharmacovigilance system by applicants. In addition, regulatory authorities will make fewer requests to submit missing information and grant more marketing authorisations. ERRATUM Erratum: Velts N.Yu. et al. Submission of Documents on the Pharmacovigilance System as Part of the Registration Dossier within the Framework of the EAEU Procedures: Analysis of Requirements and Typical Errors https://www.risksafety.ru/jour/article/view/476
- Open Access
- 6 June 2024
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 12 (2) , 190-200
Denosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
INTRODUCTION. Osteoporosis is a leading cause of morbidity, disability, reduced quality of life, and premature mortality in the elderly population. Denosumab is a treatment for osteoporosis; however, denosumab discontinuation may cause a rebound effect, which is a severe adverse drug reaction (ADR) leading to an increase in the rate of bone tissue loss. Studying the mechanism of the rebound effect and potential ways to manage it can improve the safety of denosumab therapy.AIM. This study aimed to summarise up-to-date information regarding the mechanism of the rebound effect and ways to manage it after denosumab discontinuation.DISCUSSION. Osteoporosis results from an imbalance in bone remodelling. Recent studies have shown that mature osteoclasts are able to fission into osteomorphs, which separate from the polykaryon and fuse with neighbouring osteoclasts or other osteomorphs (osteoclast recycling). The mechanism of action of denosumab is based on the inhibition of osteoclast recycling, which results in the accumulation of pre-osteoclasts and osteomorphs. Research into processes occurring in bone tissue shows that denosumab creates a pool of induced cells, and when denosumab therapy is discontinued, these induced cells quite quickly and abundantly differentiate into osteoclasts causing bone resorption (rebound effect) and increasing the risk of fractures. In order to improve mineral bone density and to prevent fractures after denosumab discontinuation, it is reasonable to use antiresorptive medicines from the bisphosphonate class. Bisphosphonates accumulate in bone tissue and concentrate in areas of active bone metabolism.CONCLUSIONS. Further studies of the rebound effect mechanism, including a deeper understanding of the role of osteomorphs in osteogenesis, will improve the measures taken to reduce the risk of fractures after denosumab discontinuation. Further research is needed to evaluate the effect of antiresorptives on bone tissue loss after denosumab discontinuation.
- 6 June 2024
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 12 (2) , 190-200
Open AccessDenosumab and the Rebound Effect: Current Aspects of Osteoporosis Therapy (Review)
INTRODUCTION. Osteoporosis is a leading cause of morbidity, disability, reduced quality of life, and premature mortality in the elderly population. Denosumab is a treatment for osteoporosis; however, denosumab discontinuation may cause a rebound effect, which is a severe adverse drug reaction (ADR) leading to an increase in the rate of bone tissue loss. Studying the mechanism of the rebound effect and potential ways to manage it can improve the safety of denosumab therapy.AIM. This study aimed to summarise up-to-date information regarding the mechanism of the rebound effect and ways to manage it after denosumab discontinuation.DISCUSSION. Osteoporosis results from an imbalance in bone remodelling. Recent studies have shown that mature osteoclasts are able to fission into osteomorphs, which separate from the polykaryon and fuse with neighbouring osteoclasts or other osteomorphs (osteoclast recycling). The mechanism of action of denosumab is based on the inhibition of osteoclast recycling, which results in the accumulation of pre-osteoclasts and osteomorphs. Research into processes occurring in bone tissue shows that denosumab creates a pool of induced cells, and when denosumab therapy is discontinued, these induced cells quite quickly and abundantly differentiate into osteoclasts causing bone resorption (rebound effect) and increasing the risk of fractures. In order to improve mineral bone density and to prevent fractures after denosumab discontinuation, it is reasonable to use antiresorptive medicines from the bisphosphonate class. Bisphosphonates accumulate in bone tissue and concentrate in areas of active bone metabolism.CONCLUSIONS. Further studies of the rebound effect mechanism, including a deeper understanding of the role of osteomorphs in osteogenesis, will improve the measures taken to reduce the risk of fractures after denosumab discontinuation. Further research is needed to evaluate the effect of antiresorptives on bone tissue loss after denosumab discontinuation.
- Open Access
- 1 September 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 12 (3) , 250-259
Methodological Approaches to Risk Management of Advanced Therapy Medicinal Products
Introduction. Advanced therapy medicinal products (ATMPs) rely on recent advances in medical science, but alongside with potential benefits they may also bring safety concerns for patients. The inherent complexity of the ATMP production and use calls for special approaches to risk management throughout their lifecycle, from obtaining the raw materials to administration to the patient.Aim. The aim of the present study was to develop approaches to risk management for ATMPs, using the example of CAR T-cell therapy.Materials and methods. The study analysed the relevant regulatory frameworks currently in force in the European Union and the United States of America, namely the regulations and guidelines adopted by the Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration and the Committee for Medicinal Products for Human Use of the European Medicines Agency.Results and discussion. The paper provides a classification of patient risks, which was developed based on the European risk-based approach. It formulates the principles of risk management for each of the risks, depending on the stage of the product life cycle. Each type of risk was considered separately. The following risk minimization strategies were determined: compliance with the good practices, ensuring the necessary qualifications or expertise of all parties involved in the product life cycle. The main element of risk control is the detailed description of the medicinal product use in the summary of product characteristics and patient information leaflet.Conclusion. The study identified the main stages at which ATMP risks may occur, and each type of risk was considered separately. The following requirements should be put in place in order to manage the ATMP risks: requirements for distributors on how to perform the product transportation and storage and to keep records for the marketing authorisation holder; requirements for healthcare facilities on how to perform the product storage, its preparation for use, advising and informing the patients on the treatment risks, symptoms of adverse events, preparatory and follow-up medical procedures, and on how to keep records for the marketing authorisation holder; requirements for the qualifications of healthcare professionals who are in charge of the product storage, its preparation for use, treatment procedures, advising and informing the patients on the treatment risks, symptoms of adverse events, and follow-up medical procedures. The data obtained will be used in the preparation of recommendations for ATMP developers.
- 1 September 2023
- Published by Center of Pharmaceutical Analytics Ltd in Drug development & registration
- Vol. 12 (3) , 250-259
Open AccessMethodological Approaches to Risk Management of Advanced Therapy Medicinal Products
Introduction. Advanced therapy medicinal products (ATMPs) rely on recent advances in medical science, but alongside with potential benefits they may also bring safety concerns for patients. The inherent complexity of the ATMP production and use calls for special approaches to risk management throughout their lifecycle, from obtaining the raw materials to administration to the patient.Aim. The aim of the present study was to develop approaches to risk management for ATMPs, using the example of CAR T-cell therapy.Materials and methods. The study analysed the relevant regulatory frameworks currently in force in the European Union and the United States of America, namely the regulations and guidelines adopted by the Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration and the Committee for Medicinal Products for Human Use of the European Medicines Agency.Results and discussion. The paper provides a classification of patient risks, which was developed based on the European risk-based approach. It formulates the principles of risk management for each of the risks, depending on the stage of the product life cycle. Each type of risk was considered separately. The following risk minimization strategies were determined: compliance with the good practices, ensuring the necessary qualifications or expertise of all parties involved in the product life cycle. The main element of risk control is the detailed description of the medicinal product use in the summary of product characteristics and patient information leaflet.Conclusion. The study identified the main stages at which ATMP risks may occur, and each type of risk was considered separately. The following requirements should be put in place in order to manage the ATMP risks: requirements for distributors on how to perform the product transportation and storage and to keep records for the marketing authorisation holder; requirements for healthcare facilities on how to perform the product storage, its preparation for use, advising and informing the patients on the treatment risks, symptoms of adverse events, preparatory and follow-up medical procedures, and on how to keep records for the marketing authorisation holder; requirements for the qualifications of healthcare professionals who are in charge of the product storage, its preparation for use, treatment procedures, advising and informing the patients on the treatment risks, symptoms of adverse events, and follow-up medical procedures. The data obtained will be used in the preparation of recommendations for ATMP developers.
- Open Access
- 9 February 2023
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 67 (11-12) , 79-90
Ototoxicity of Aminoglycosides the Modern Concepts
Aminoglycosides are broad-spectrum antibacterial agents used in the treatment of urinary tract infections, tuberculosis, visceral leishmaniasis, sepsis in newborns, as well as cystic fibrosis. However, the use of aminoglycosides is limited due to their ototoxicity — the risk of developing serious adverse reactions, in particular, persistent irreversible hearing loss and vestibular disorders associated with the death of hair cells in the inner ear. The review analyzes scientific data on the possible mechanisms of aminoglycosides’ damaging effect on the hair cells of the inner ear. Genetically determined causes contributing to the manifestation of ototoxic properties of drugs of this group are described. The necessity of genetic screening for the carriage of mutations m.1555A>G and m.1494C>T in the MT-RNR1 gene of mitochondrial DNA is substantiated in order to minimize the risk of hearing disorders in patients with hereditary predisposition. Understanding the mechanisms of ototoxicity of aminoglycosides will make it possible to find ways to prevent and correct hearing loss after their use.
- 9 February 2023
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 67 (11-12) , 79-90
Open AccessOtotoxicity of Aminoglycosides the Modern Concepts
Aminoglycosides are broad-spectrum antibacterial agents used in the treatment of urinary tract infections, tuberculosis, visceral leishmaniasis, sepsis in newborns, as well as cystic fibrosis. However, the use of aminoglycosides is limited due to their ototoxicity — the risk of developing serious adverse reactions, in particular, persistent irreversible hearing loss and vestibular disorders associated with the death of hair cells in the inner ear. The review analyzes scientific data on the possible mechanisms of aminoglycosides’ damaging effect on the hair cells of the inner ear. Genetically determined causes contributing to the manifestation of ototoxic properties of drugs of this group are described. The necessity of genetic screening for the carriage of mutations m.1555A>G and m.1494C>T in the MT-RNR1 gene of mitochondrial DNA is substantiated in order to minimize the risk of hearing disorders in patients with hereditary predisposition. Understanding the mechanisms of ototoxicity of aminoglycosides will make it possible to find ways to prevent and correct hearing loss after their use.
- Open Access
- 31 January 2023
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 11 (1) , 22-29
Pharmacovigilance System Master File: An Overview of Changes in the EAEU Good Pharmacovigilance Practice
Мастер-файл системы фармаконадзора: обзор изменений в Правилах надлежащей практики фармаконадзора ЕАЭС
- 31 January 2023
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 11 (1) , 22-29
Open AccessPharmacovigilance System Master File: An Overview of Changes in the EAEU Good Pharmacovigilance Practice
Мастер-файл системы фармаконадзора: обзор изменений в Правилах надлежащей практики фармаконадзора ЕАЭС
- Open Access
- 5 October 2022
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 10 (3) , 259-268
Analysis of the Causes for Renal Dysfunction during Antibiotic Therapy in a Patient with Lyme Disease
Adverse drug reactions (ADRs) are recorded throughout the lifecycle of a medicinal product. In the post-marketing period, new ADRs are primarily identified via drug safety signals. In order to assess a signal and establish causality between an adverse drug reaction and a suspected medicinal product, it is necessary to evaluate the signal strength and quality.The aim of the study was to analyse the information submitted to Russian regulatory authorities by a patient and check it for a potential causal association of acute tubulointerstitial nephritis (ATIN) with the use of ceftriaxone and with the patient’s principal diagnosis, Lyme disease.Materials and methods: the authors analysed the patient’s submission received by the Ministry of Health of the Russian Federation in 2022 with a complaint that the treatment of Lyme disease with ceftriaxone had caused ATIN. The probability of a causal relationship between the medicinal product and the ADR was evaluated using the Naranjo algorithm.Results: according to the review of literature and the spontaneous reports collected in Pharmacovigilance 2.0, the database in the Automated Information System of the Russian Federal Service for Surveillance in Healthcare, both ceftriaxone and the underlying condition (Lyme disease) may cause renal abnormalities. Ceftriaxone is potentially nephrotoxic; it mainly affects the tubular system of the kidneys. Borreliosis may cause kidney damage as well; such damage manifests clinically as rapidly progressing and fatal damage to the glomeruli.Conclusions: the probability of a causal relationship between the development of ATIN in the complainant and the use of ceftriaxone was categorised as “possible”. However, the information available did not allow for establishing a definite relationship between kidney damage and the use of the medicinal product. Further monitoring of similar cases is necessary to minimise the risks of developing this pathology during treatment with ceftriaxone.
- 5 October 2022
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 10 (3) , 259-268
Open AccessAnalysis of the Causes for Renal Dysfunction during Antibiotic Therapy in a Patient with Lyme Disease
Adverse drug reactions (ADRs) are recorded throughout the lifecycle of a medicinal product. In the post-marketing period, new ADRs are primarily identified via drug safety signals. In order to assess a signal and establish causality between an adverse drug reaction and a suspected medicinal product, it is necessary to evaluate the signal strength and quality.The aim of the study was to analyse the information submitted to Russian regulatory authorities by a patient and check it for a potential causal association of acute tubulointerstitial nephritis (ATIN) with the use of ceftriaxone and with the patient’s principal diagnosis, Lyme disease.Materials and methods: the authors analysed the patient’s submission received by the Ministry of Health of the Russian Federation in 2022 with a complaint that the treatment of Lyme disease with ceftriaxone had caused ATIN. The probability of a causal relationship between the medicinal product and the ADR was evaluated using the Naranjo algorithm.Results: according to the review of literature and the spontaneous reports collected in Pharmacovigilance 2.0, the database in the Automated Information System of the Russian Federal Service for Surveillance in Healthcare, both ceftriaxone and the underlying condition (Lyme disease) may cause renal abnormalities. Ceftriaxone is potentially nephrotoxic; it mainly affects the tubular system of the kidneys. Borreliosis may cause kidney damage as well; such damage manifests clinically as rapidly progressing and fatal damage to the glomeruli.Conclusions: the probability of a causal relationship between the development of ATIN in the complainant and the use of ceftriaxone was categorised as “possible”. However, the information available did not allow for establishing a definite relationship between kidney damage and the use of the medicinal product. Further monitoring of similar cases is necessary to minimise the risks of developing this pathology during treatment with ceftriaxone.
- Open Access
- 2 June 2022
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 10 (2) , 196-199
Safety of Antibacterial and Antiprotozoal Medicinal Products
The experts of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on the recalls of antibacterial and antiprotozoal medicinal products and/or the need for labelling updates due to changes in the safety profile. The analysis revealed 16 decisions containing information on the following medicines registered in Russia: ertapenem, сeftriaxone, cefazolin, аmoxicillin, сefoperazone+sulbactam, piperacillin+tazobactam, сlindamycin, teicoplanin, rifampin, co-trimoxazole, hydroxychloroquine.
- 2 June 2022
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 10 (2) , 196-199
Open AccessSafety of Antibacterial and Antiprotozoal Medicinal Products
The experts of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on the recalls of antibacterial and antiprotozoal medicinal products and/or the need for labelling updates due to changes in the safety profile. The analysis revealed 16 decisions containing information on the following medicines registered in Russia: ertapenem, сeftriaxone, cefazolin, аmoxicillin, сefoperazone+sulbactam, piperacillin+tazobactam, сlindamycin, teicoplanin, rifampin, co-trimoxazole, hydroxychloroquine.
- Open Access
- 18 October 2021
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 9 (4) , 185-190
Analysis of Noncompliances with Legislative Requirements in Pharmacovigilance Materials of Registration Dossiers
Since 1 January 2021 the authorisation of medicines in the Russian Federation has to be performed according to the Eurasian Economic Union (EAEU) procedure. The Pharmacovigilance System Master File (PSMF) is the main document describing the pharmacovigilance system of the marketing authorisation holder (MAH) or its authorised representative. The aim of the study was to analyse noncompliances with the EAEU requirements, which were revealed during PSMF assessment.Materials and methods: the authors analysed 687 pharmacovigilance documents included in registration dossiers that were submitted for assessment from 1 January to 30 June, 2021. Results: the authors identified and systematised the main noncompliances with the EAEU requirements in terms of presentation, content, completeness of each PSMF section. They analysed the frequency of noncompliances in PSMFs and identified the most frequent flaws of MAHs’ pharmacovigilance systems.Conclusions: the authors give recommendations for elimination of significant noncompliances identified during PSMF assessment, which may include: timely updating, maintenance, and revision of the documents in accordance with changes in legislation and any other significant changes, regular training of pharmacovigilance staff, etc. The results of this review will be useful for MAHs as the main participants of the marketing authorisation process who are directly involved in the pharmacovigilance system management at the pre- and post-authorisation stages, and will help them prevent potential mistakes when drawing up pharmacovigilance system documents.
- 18 October 2021
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 9 (4) , 185-190
Open AccessAnalysis of Noncompliances with Legislative Requirements in Pharmacovigilance Materials of Registration Dossiers
Since 1 January 2021 the authorisation of medicines in the Russian Federation has to be performed according to the Eurasian Economic Union (EAEU) procedure. The Pharmacovigilance System Master File (PSMF) is the main document describing the pharmacovigilance system of the marketing authorisation holder (MAH) or its authorised representative. The aim of the study was to analyse noncompliances with the EAEU requirements, which were revealed during PSMF assessment.Materials and methods: the authors analysed 687 pharmacovigilance documents included in registration dossiers that were submitted for assessment from 1 January to 30 June, 2021. Results: the authors identified and systematised the main noncompliances with the EAEU requirements in terms of presentation, content, completeness of each PSMF section. They analysed the frequency of noncompliances in PSMFs and identified the most frequent flaws of MAHs’ pharmacovigilance systems.Conclusions: the authors give recommendations for elimination of significant noncompliances identified during PSMF assessment, which may include: timely updating, maintenance, and revision of the documents in accordance with changes in legislation and any other significant changes, regular training of pharmacovigilance staff, etc. The results of this review will be useful for MAHs as the main participants of the marketing authorisation process who are directly involved in the pharmacovigilance system management at the pre- and post-authorisation stages, and will help them prevent potential mistakes when drawing up pharmacovigilance system documents.